Funding Support and Author Disclosures Dr Tsimikas is supported by NHLBI grants R01 HL159156 and HL170224; is a co-inventor and receives royalties from patents owned by University of California-San Diego (UCSD); is a co-founder and has an equity interest in Oxitope and Kleanthi Diagnostics; and has a dual appointment at UCSD and Ionis Pharmaceuticals; although these relationships have been identified for conflict-of-interest management based on the overall scope of the project, the research findings included in this particular publication may not necessarily relate to the interests of the above companies; the terms of this arrangement have been reviewed and approved by UCSD, in accordance with its conflict-of-interest policies. Dr Bittner has received grant support from Sanofi, Regeneron Pharmaceuticals, Amgen, AstraZeneca (completed), DalCor (completed), Esperion (completed), and Novartis; has received consulting fees from Pfizer (completed in 2021); has received honoraria from Medscape and the National Lipid Association; and has received fees for participating on Data Safety Monitoring Boards for the National Institutes of Health and for Verve Therapeutics.